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stroke or other significant morbidity. As such, there is a
pervasive impression that those (trial ineligible) patients
are at higher risk for perioperative stroke with CEA.
Accordingly, carotid stenting may be perceived as a safer
treatment than CEA in these patients. Data supporting
this position, however, are largely anecdotal.
Current randomized trials comparing CEA with stent-
ing (Carotid Revascularization Endarterectomy versus
Stent Trial1) have nonrandomized “registry” arms for
patients who do not qualify for the trial but are found to
be “high risk” for CEA. Unfortunately, a similar “high
risk” control group of surgically treated patients is lacking.
The purpose of this study was to assess potential differ-
ences in outcome after CEA between patients who were
“trial eligible” and patients who were “trial ineligible.”
These results were then compared with current outcomes
from carotid stenting.
METHODS
Patients who underwent CEA during a consecutive 2-
year period (Dec 31, 1996 to Dec 31, 1998) at Alton
Ochsner Medical Foundation were retrospectively identi-
fied through the hospital database. All patients were
included with the exception of patients undergoing com-
bined or sequential procedures during the same hospital-
ization (ie, coronary artery bypass grafting and CEA or
vertebral artery transposition and CEA). All volumes of
hospital admission charts and clinic charts were reviewed.
A telephone survey was performed if specific information
was unavailable from the hospital record. Each patient was
evaluated and categorized, according to the original exclu-
It is axiomatic that interventional treatment of signifi-
cant carotid artery occlusive disease should be performed
by the method that provides the least periprocedural risk
and best durability while providing long-term freedom
from stroke. Until recently, the only viable nonmedical
treatment of carotid disease was endarterectomy. With the
advent of percutaneous carotid treatment through the
techniques of angioplasty and stenting, a second interven-
tional treatment modality is now available.
As with most other disease processes, the choice of
treatment should be individualized to each patient. Herein
lies the most significant controversy surrounding inter-
ventional carotid therapy. Are there subgroups of patients
that, when treated with carotid stenting, have equivalent
or reduced neurologic morbidity when compared with
patients treated with carotid endarterectomy (CEA)?
Proponents of carotid stenting have frequently sug-
gested that the outcomes of CEA in the North American
Symptomatic Carotid Endarterectomy Trial (NASCET)
and Asymptomatic Carotid Atherosclerosis Study (ACAS)
cannot be generalized to the general population. The
entry criteria for these trials indeed excluded many
patients who might have a higher risk for perioperative
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Purpose: Proponents of carotid angioplasty and stenting suggest that “high risk” patients, defined as patients excluded
from the North American Symptomatic Carotid Endarterectomy Trial (NASCET) and Asymptomatic Carotid
Atherosclerosis Study (ACAS), may have a significantly higher risk of stroke with carotid endarterectomy (CEA).
However, this selected patient cohort has been poorly studied.
Methods: A retrospective review of patients who underwent CEA during a 2-year period at a tertiary referral institution
was performed. Each patient was evaluated and categorized, according to the exclusion criteria, by NASCET and ACAS
standards. Statistical analysis using χ2 and Fisher exact tests was performed.
Results: There were 366 CEAs performed on 348 patients, including 32 (8.7%) for recurrent stenosis. A subgroup of
169 (46.2%) patients were trial ineligible. Focal ipsilateral symptoms were present in 148 (40.4%) of the patients. There
were 9 (2.5%) strokes and 1 (0.3%) death, secondary to a major stroke, for an overall stroke and death rate of 2.5%.
Trial-eligible patients had a stroke/death rate of 1.5% (3/197) while trial-ineligible patients had a 3.6% (6/169)
stroke/death rate (P = .17).
Conclusion: Patients who were considered high risk for CEA as defined by trial ineligibility were common, comprising
approximately half of our patients. Although trial-ineligible patients had a nonsignificant trend toward higher neuro-
logic morbidity when compared with the eligible group, the risks were still comparable with NASCET/ACAS results.
CEA was a safe procedure even in this “high risk” group. As such, ineligibility for a randomized carotid intervention
trial should not be employed as a “de novo” indication for carotid stenting. (J Vasc Surg 2001;34:581-6.)
sion criteria (Table I), by NASCET2 and ACAS3 standards.
In keeping within the criteria for age exclusion for the tri-
als, age was evaluated as either <80 years or ≥80 years.
Complete exclusion criteria not provided within the pub-
lished studies (ie, ACAS) were obtained through personal
correspondence. Patients were categorized as NASCET
trial eligible, ACAS trial eligible, or trial ineligible.
Definitions. Patients were classified for analysis as
having asymptomatic or symptomatic carotid stenosis.
Lateralizing symptoms included transient ischemic attack,
previous stroke, and amaurosis fugax. Patients with non-
lateralizing global ischemic symptoms of dizziness, syn-
cope, or presyncope were considered to be asymptomatic.
Symptomatic patients were classified as patients who expe-
rienced an ipsilateral neurologic event within 120 days
before the procedure. As per NASCET guidelines,
patients with lateralizing symptoms occurring more than
120 days after CEA were considered asymptomatic. Stroke
was defined as a new neurologic sign that lasted for ≥24
hours. Minor strokes were defined as events causing min-
imal neurologic deficit that resolved with minimal or no
deficit at the 30-day examination. Major strokes were
defined as deficits that lasted beyond 30 days and caused a
change in the lifestyle of the patient.4 All events occurring
within 30 days of surgery were included.
Preoperative evaluation. Patients were evaluated pre-
operatively by an accredited vascular laboratory using duplex
ultrasonography and the Bluth criteria to categorize degree
of stenosis.5 The vascular laboratory was certified by the
Intersocietal Commission for the Accreditation of Vascular
Laboratories, having satisfactorily correlated duplex ultra-
sonographic velocity criteria to anatomic angiographic
results as part of the institution’s participation in the ACAS
trial. Stenosis was categorized into 80% to 99% (peak systolic
velocity [PSV] > 250; peak diastolic velocity [PDV] > 100;
systolic velocity ratio internal carotid artery/common
carotid artery [ratio] > 3.7), 60% to 79% (PSV > 130; PDV
> 40; ratio > 1.8), and 40% to 59% (PSV, 110-129; PDV <
40; ratio < 1.8). Cerebral arteriography was used selectively
at the discretion of the operating surgeon for cases in which
the symptoms did not correlate with the vascular laboratory
studies or those with recurrent stenoses or previous neck
radiation.6 Some patients underwent arteriography before
vascular surgery consultation. Angiography was performed
in 109 (29.3%) patients, including 32 patients with recur-
rent stenosis, 100% of whom underwent angiography. The
remaining 257 (70.2%) patients had duplex ultrasonography
alone before operative intervention.
Operative details. General endotracheal anesthesia
was used in the majority of operations, with cervical block
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Table I. NASCET and ACAS exclusion criteria
Criteria NASCET exclusions ACAS exclusions
Age (y) >79 <40 or >79
Symptoms Asymptomatic, ipsilateral >120 days before CEA Ipsilateral symptoms or VBI, or contralateral
symptoms within 45 days of CEA
History of FMD, tumor, AVM, etc, History of FMD, tumor, AVM, etc, that could
that could cause symptoms cause symptoms, seizure disorder or migraines
Stroke in evolution Stroke in evolution
Previous CVA with profound deficit, either side Previous CVA with profound deficit, either side
Lesion <30% or occluded <60% or occluded (by ACAS)
Tandem lesion > target stenosis Tandem lesion > target stenosis
Unsuitable for CEA Unsuitable for CEA
Surgical Hx Previous ipsilateral CEA Previous ipsilateral CEA
Previous contralateral CEA within 4 months No exclusion
Major surgery within 1 month Major surgery within 1 month
Comorbidities Kidney failure Kidney failure (creatinine >3)
Lung failure Lung failure (impact 5-y survival)
Liver failure Liver failure
Cancer, <50% 5-y survival Cancer, <50% 5-y survival
Atrial fibrillation Atrial fibrillation
Valvular heart disease Valvular heart disease 
(including valve replacement)
Uncontrolled DM Uncontrolled DM (fasting glucose >400 mg/dL)
Uncontrolled HTN Uncontrolled HTN (>180 systolic, 
115 diastolic, ×3)
Unstable angina Unstable angina
MI within 6 months No exclusion
Symptomatic CHF Symptomatic CHF
No exclusion Radiation treatment to neck
No exclusion Active ulcer disease
Allergies Aspirin Aspirin
No exclusion Coumadin use
VBI, Vertebrobasilar insufficiency; FMD, fibromuscular dysplasia; AVM, arterial venous malformation; ACAS, Asymptomatic Carotid Atherosclerosis Study;
DM, diabetes mellitus; HTN, hypertension; MI, myocardial infarction; CHF, congestive heart failure.
or local anesthesia alone used in less than 5%. Although
there were minor variations in technique, all surgeons
employed classical endarterectomy as popularized by Dr
Jesse Thompson.7 Eversion endarterectomy was not per-
formed. Most vessels were patched (81%), and shunts
were used liberally (92%). Intraoperative postendarterec-
tomy duplex ultrasonography and arteriography were
employed sparingly.
Statistics. Statistical analysis was performed using χ2
analysis for more frequent occurrences. When χ2 analysis
was not appropriate for less frequent occurrences, a Fisher
exact test was performed. Any value expressed as P < .05
was considered significant.
PATIENTS
Demographics. There were 366 carotid endarterec-
tomies performed in 348 patients between December 31,
1996 and December 31, 1998. The study group was pre-
dominantly male (63.4%) with a mean age of 68.9 years (±
9.9). Table II lists the comorbidities of the study group
with a breakdown based on trial eligibility. Trial ineligible
patients had a statistically higher prevalence of peripheral
arterial disease (P =.016), atrial fibrillation (P = .02), and
congestive heart failure (P = .0001) and a trend toward
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chronic renal insufficiency (P = .08). Hypercholesterolemia
was more common in patients who were ACAS eligible 
(P = .004).
Focal ipsilateral symptoms within 120 days of CEA
(Table III) were present in 40.4% (148) of the patients, 86
with transient ischemic attacks (TIA), 41 with previous
ipsilateral stroke, and 21 with amaurosis fugax. Patients
with ipsilateral events occurring > 120 days before CEA
were considered asymptomatic. Global ischemic symp-
toms were present in 2.5% (9) of the patients and were
included in the 59.6% (218) of patients who were asymp-
tomatic.
The severity of stenosis is presented in Fig 1. Most
asymptomatic patients (177/218, 81.2%) had high-grade
(80%-99%) stenosis by duplex ultrasonography, with the
remainder having moderate (60%-79%) stenosis. In symp-
tomatic patients, 54.7% (81/148) had 80% to 99% steno-
sis, 33.8% (50/148) had 60% to 79% stenosis and the
remaining eight (5.4%) patients had 40% to 59% stenosis.
Table II. Patient comorbidity
ACAS eligible NASCET eligible
Total (n = 366) (n = 127) (n = 70) Ineligible (n = 169) P value
Mean age 68.9 ± 8.6 67.4 ± 7.7 66.2 ± 7.8 71.4 ± 8.9 .016
Male 63.4% (232) 63.8% (81) 71.4% (50) 60.1% (101) .212
CAD 56.6% (207) 52.8% (67) 58.6% (41) 58.5% (99) .585
HTN 80.9% (296) 78.0% (99) 77.1% (54) 84.6% (143) .246
PAD 39.6% (145) 30.7% (39) 37.1% (26) 47.3% (80) .016
IDDM 7.9% (30) 8.7% (11) 7.1% (5) 8.3% (14) .923
NIDDM 19.7% (73) 18.9% (24) 14.3% (10) 23.1% (39) .312
CRI 4.1% (16) 2.4% (3) 1.4% (1) 7.1% (12) .081
HCL 33.3% (122) 44.1% (56) 31.4% (22) 26.0% (44) .004
COPD 12.0% (44) 7.9% (10) 10.0% (7) 16.0% (27) .286
AFIB 1.6% (6) 0.0% (0) 0.0% (0) 3.0% (6) .020
CHF 6.0% (22) 1.6% (2) 0.0% (0) 11.3% (20) .0001
CAD, Coronary artery disease; HTN, hypertension; PAD, peripheral arterial disease; IDDM, insulin dependent diabetes mellitus; NIDDM, non–insulin-
dependent diabetes mellitus; CRI, chronic renal insufficiency; HCL, hypercholesterolemia; COPD, chronic obstructive pulmonary disease; AFIB, atrial fib-
rillation; CHF, congestive heart failure.
Table III. Indications






Global ischemia 4.1% (9/218)
No symptoms 95.9% (209/218)
*Any neurologic event >120 days before CEA was considered asympto-
matic.
Amaurosis, Amaurosis fugax.
Fig 1. Bar graph illustrating the degree of preoperative stenosis
by carotid duplex for asymptomatic versus symptomatic patients
with carotid stenosis.
All of the patients with 40% to 59% stenosis underwent
angiography, and most were found to have significant
associated ulceration.
RESULTS
Trial eligibility. Patient breakdown by trial eligibility
is depicted in Fig 2. Approximately half of these patients
(169, 46.2%) were ineligible by either NASCET or ACAS
criteria. Approximately one third (34.7%) of patients were
ACAS eligible and 19.1% were NASCET eligible.
Reoperative CEA was performed on 32 (8.7%) of the 366
patients. They are included in the trial ineligible group,
excluded from the trials for recurrent stenosis.
Perioperative outcomes: Neurologic events and
death. There were 9 strokes (2.5%) and 1 death (0.3%)
secondary to a major stroke, producing an overall stroke
and death rate of 2.5%. All strokes occurred in the ipsilat-
eral hemisphere to the CEA. Four of the events were
major strokes and five were minor, for an overall com-
bined major stroke and death rate of 1.1%. Among the
148 (40.4%) patients who underwent CEA for sympto-
matic carotid stenosis, 4 strokes (2.7%) occurred (Table
IV). Two of the strokes were major and two were minor,
with no deaths, for an overall major stroke rate of 1.4%. A
total of 218 (59.6%) CEAs were performed for asympto-
matic carotid stenosis with five (2.3%) strokes seen in this
group of patients. Two of these events were considered
major strokes, including a death, for a major stroke and
death rate of 0.9% in asymptomatic patients. There was
not a statistical difference between the stroke rate in symp-
tomatic and asymptomatic patients (P = .39) Patients with
recurrent stenosis had a stroke/death rate of 3.1% (1/32).
Neurologic events were further analyzed based upon
NASCET or ACAS trial eligibility (Table V). There were
3 strokes (1.5%) seen in the trial-eligible patients, 1 major
stroke and 2 minor strokes, for a major stroke/death rate
of 0.5%. The trial ineligible patients experienced 6 strokes
(3.5%), 3 minor and 3 major, for an overall major stroke
and death rate of 1.7%. The trend toward a higher stroke
rate in the trial ineligible patients versus trial eligible
patients did not reach statistical significance (P = .17).
In the entire patient sample, peripheral arterial occlu-
sive disease was present in 39.6% and was associated with
a nonsignificant trend (P = .09) for perioperative stroke.
No other patient demographic characteristic demon-
strated an increased correlation with perioperative events.
Octagenerians. Patients ≥80 years old were sepa-
rately analyzed. There were 42 such patients in this group,
with a mean age of 82.8 years. There were no deaths and
one stroke for an overall stroke and death rate of 2.4%, not
significantly different from the 2.5% in the entire patient
cohort. Comorbidities were similar, except for less coro-
nary artery disease (40.5% vs 56.6%) and hypercholes-
terolemia (21.4% vs 33.3%) in the ≥80-year-old patients
than in the entire patient cohort.
Morbidity: Medical/surgical. There were two
(0.5%) perioperative myocardial infarctions experienced in
the entire cohort, one in each of the trial-eligible and trial
ineligible groups. Both patients recovered with supportive
care and minimal increase in length of hospitalization.
Nine (2.5%) patients suffered from some form of respira-
tory failure. Seven of those patients required aggressive
pulmonary toilet to fully recover, and two patients needed
ventilatory support. One of these patients also had a
stroke and died. The other patient recovered and was dis-
charged on the tenth day after surgery. One patient (0.3%)
had acute renal failure and also experienced stroke, respi-
ratory failure, multisystem organ failure, and, ultimately,
death.
Seven patients (1.9%) required surgical intervention
for neck hematomas; an additional 18 patients (4.9%) had
neck hematomas that resolved with expectant manage-
ment. Twenty-six (7.1%) patients experienced cranial
nerve injuries. The large majority (23, 85.2%) fully
resolved, with one persistent nerve palsy (0.3%). Follow-
up was unavailable on 3 patients. Wound infections were
uncommon, observed in only 3 (0.9%) patients. One
(0.3%) of the patients with a wound infection required
excision of the prosthetic patch and repair with a saphe-
nous vein interposition graft.
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Table IV. Neurologic events/preoperative symptomatology
Symptom status Patients Total strokes Major stroke Minor stroke
Symptomatic 148 (40.4%) 4 (2.7%) 2 (1.4%) 2 (1.4%)
Asymptomatic 218 (59.6%) 5 (2.3%) 2 (0.9%) 3 (1.4%)
Total 366 9 (2.5%) 4 (1.1%) 5 (1.4%)
Table V. Neurologic events/trial eligibility
Carotid disease Eligible patients (CVA) Ineligible patients (CVA) P value
Symptomatic (NASCET) 1.4% (1/70) 4.4% (3/68) .3
Asymptomatic (ACAS) 1.6% (2/127) 3.0% (3/101) .39
Total 1.5% (3/197) 3.6% (6/169) .17
Length of stay. Length of stay (LOS) is presented in
Fig 3. The majority of patients were discharged on the first
postoperative day (59%), with 81% being discharged by 2
days after surgery. Median LOS was 1 day, and the mean
LOS was 2.08 days (± 2.2). Many of the patients with
longer hospitalizations were originally admitted with acute
neurologic changes, such as TIA or stroke, who, after neu-
rologic evaluation and stabilization, underwent CEA dur-
ing the same admission.
The patients who were ≥80 years old had similar LOS
(median, 1 day; mean, 2.05 [± 2.3]). The majority of
these patients were also discharged of the first postopera-
tive day (61.9%), with all but one patient discharged by
the second postoperative day. The only patient who
remained in the hospital longer than the second postoper-
ative day suffered the only stroke in this subgroup.
DISCUSSION
There are two important findings in this study. The
first is that “high risk” patients, as defined by being trial
ineligible, are common in a tertiary care referral practice,
constituting nearly half of our patients. When compared
with trial-eligible patients, patients not eligible for the
NASCET or ACAS trials had a trend toward a higher peri-
operative stroke/death rate (3.6% [6/169] vs 1.5%
[3/197]). Although this difference was not statistically
significant (P = .17), the trend seems intuitive; patients
with known risk factors for higher perioperative neuro-
logic morbidity (crescendo TIAs, uncontrolled hyperten-
sion, recurrent disease, significant renal insufficiency) were
all included in the ineligible cohort. Despite these risk fac-
tors, the “high risk,” trial ineligible patients had outcomes
that fell within the American Heart Association8 suggested
guidelines for acceptable perioperative stroke/death after
CEA (3% asymptomatic, 6% symptomatic). In patients
who were trial eligible, our stroke/death rate for asymp-
tomatic patients (1.5%) was similar to that of ACAS
(2.2%), and that for symptomatic patients (1.6%) com-
pared favorably with NASCET (5.8%).
In the years after publication of the NASCET/ACAS
trial data, much has been written regarding the relative
limitations of generalizing those benchmark results. One
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issue has been that of surgical expertise; surgeons involved
in the trials had a track record of excellent results. Reports
of unacceptable neurologic perioperative complication
rates published from uncontrolled community studies
prompted some to suggest that the required surgical
expertise was not available to most patients.9 The second
major variable is that of patient selection. Could the trial
results be duplicated in an unselected group of patients?
In an effort to answer these questions, Hallett et al10
compared a 25-year, population-based result of CEA (n =
297) with that of NASCET and found that the
stroke/death rates were comparable. They concluded that
NASCET results were applicable to “general community
practice.” However, no attempt was made to stratify
patients as to their trial eligibility.
In a study of 113,300 Medicare patients undergoing
CEA, Wennberg et al11 found significantly higher mortal-
ity rates than those in NASCET (0.6%) and ACAS (0.1%).
In hospitals that had participated in the trials, a mortality
rate of 1.4% was documented, which increased to 2.5% in
nontrial, low-volume hospitals. Wennberg and colleagues
concluded that caution must be exercised in generalizing
trial results to the general population. In the current study,
there was no mortality in trial-eligible patients (n = 197)
and one death in a trial-ineligible patient (0.6%, n = 169)
for an overall mortality rate of 0.3% (1/366).
Carotid endarterectomy in octogenarians has been
studied extensively with both supportive and cautionary
conclusions as to its appropriateness and safety. The
stroke/death rate in the octogenarians in this series (2.4%)
was comparable with the entire patient cohort (2.5%) and
intermediate between the trial-eligible (1.5%) and trial-
ineligible (3.6%) patients. Therefore, age did not appear to
be a significant factor in the nonsignificant trend toward a
higher risk of stroke in trial-ineligible patients.
Comparison with carotid stenting. Wholley et al12
recently published results of carotid stenting from a global
registry (n = 4757 patients). These results were tabulated
Fig 3. Average length of stay for entire cohort of patients.
Fig 2. Breakdown of patient sample based on trial eligibility (N =
366).
from multiple centers worldwide who wished to share
their results. A self-selection bias likely occurred, in that
physicians with relatively poor results might be less inter-
ested in participating in the survey. As such, these data
likely approximate the best results available currently.
They reported a minor stroke rate of 2.72% and a major
stroke rate of 1.49% for an overall stroke rate of 4.21%.
The mortality rates were divided into neurologic (proce-
dure-related) and non-neurologic (non–procedure
related) at 0.86% and 1.22%, respectively, giving a com-
bined periprocedural mortality rate of 2.08%. The mortal-
ity rate in our surgical group (0.3%) was significantly
lower, including all “high risk” (trial-ineligible) patients.
Combining their numbers produced an overall 30-day
stroke/death rate of 6.29% for this collective study. These
patients were not stratified as to their trial eligibility. Our
stroke/death rate (2.5% overall, 1.5% trial eligible, 3.6%
trial ineligible) compared favorably, even in the “high risk”
trial-ineligible group.
Even the proponents of carotid stenting consider its
use to be too high a risk in older patients. Chastain et al13
published a series on patients undergoing carotid angio-
plasty and stenting that was grouped according to age.
They reported neurologic complication rates of 25% (1
major stroke and 4 minor strokes) in patients who were
≥80 years of age. They concluded that this group of
patients was at increased risk and needed extensive coun-
seling before carotid stenting. The stroke rate of 2.4% in
the patients 80 years or older in this study is markedly
lower and supports the safety of carotid endarterectomy in
the aging population.
The percentage of asymptomatic patients in the current
series deserves comment. The majority of patients (59.6%)
were asymptomatic from 1997 to 1998, similar to the find-
ings of Hertzer et al.14 It should be noted that the defini-
tion of a symptomatic lesion in the current series was strict,
with exclusion of patients with global ischemic symptoms
and patients with lateralizing symptoms >120 days before
CEA. In 1994, only 34% of our patients undergoing CEA
were asymptomatic.15 Our enthusiasm for treating asymp-
tomatic severe stenosis was buoyed by our participation in,
and the subsequent publication of, the ACAS results.
Limitations of study. As a retrospective study, this
work has the inherent limitations of a nonprospective
study. Because event rates were low, the relative lack of
power did not allow definitive statistical analysis. The non-
significant P value of .17 between the eligible and ineligi-
ble groups likely represented a type II error that might be
remedied by an increase in the sample size. However, the
trends seen in this sample size (n = 366) were unlikely to
be have occurred by chance.
Conclusions. CEA in experienced hands appears to
have a very low risk of perioperative stroke or death.
Patients who are trial ineligible do show a trend toward
higher neurologic morbidity, but these rates are still within
the suggested standards set by the AHA. As importantly,
this group of “high risk” patients have outcomes from
CEA that compare favorably with those of carotid stent-
ing. Treatment decisions should be individualized, but on
the basis of this study, trial ineligibility per se should not
be considered a reason to eschew CEA in favor of carotid
stenting.
Thanks to Richard Chambers, MSPH, for performing
the statistical analysis for this study.
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